Nicole White
Corporate Officer/Principal at ASSEMBLY BIOSCIENCES, INC.
Net worth: 194 723 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jason Okazaki | M | 48 | 4 years | |
| John McHutchison | M | 66 | 14 years | |
| William Ringo | M | 78 | 10 years | |
| Bryan Giraudo | M | 49 | 6 years | |
| Susan Mahony | M | 59 | 7 years | |
| John O. Gunderson | M | - | 2 years | |
| Anthony Altig | M | 68 | 12 years | |
| Michael Houghton | M | 73 | 3 years | |
| Russell Cox | M | 60 | 6 years | |
| Gina Consylman | F | 52 | 4 years | |
| Jeanette Bjorkquist | F | - | 5 years | |
| Lisa Johnson-Pratt | M | 60 | 3 years | |
| Anuj Gaggar | M | 46 | 1 years | |
| Shannon Ryan | F | - | - | |
| Chan Beals | M | - |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 8 years |
| William Delaney | M | 52 | 4 years | |
| Tomas Cihlar | M | 57 | 1 years | |
| Jennifer A. Troia | F | - | 7 years | |
| Linda Higgins | M | 62 | 14 years | |
| Robert Cook | M | 65 | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Uri Lopatin | M | 52 | 17 years | |
| Michael Samar | M | 51 | 5 years | |
| Thomas Russo | M | 52 | 9 years | |
| Gordon Earle Moore | M | 95 | 17 years | |
| Per Wold-Olsen | M | 76 | - | |
| Otello Stampacchia | M | 55 | 1 years | |
| Kevin Lofton | M | 69 | 15 years | |
| David Dornan | M | 46 | 5 years | |
| Wen Kai Xiang | M | - | - | |
| Monica Tellado | F | 51 | 9 years | |
| Alan J. Lewis | M | 78 | 5 years | |
| Laura Carter | M | 57 | 4 years | |
| Myron Holubiak | M | 77 | 12 years | |
| Josh Bilenker | M | 52 | 5 years | |
| Paul A. Berg | M | 97 | 13 years | |
| James M. Denny | M | 91 | 17 years | |
| Richard DiMarchi | M | 71 | 9 years | |
| Renée Galá | F | 52 | 6 years | |
| Diana Brainard | M | 53 | 6 years | |
| Susannah Cantrell | M | - | 8 years | |
| Carla Fiankan | F | - | 7 years | |
| Kenneth Lynard | M | 56 | 4 years | |
| Roger Dansey | M | 67 | 1 years | |
| Shao Lee Lin | M | 57 | 3 years | |
| Matthew Lang | M | 47 | 8 years | |
| Erik Emerson | M | 53 | 3 years | |
| Wayne Godfrey | M | 63 | 3 years | |
| Dennis D. Self | M | 59 | 2 years | |
| Rajesh Krishnan | M | 51 | 5 years | |
| Erin Quirk | M | 53 | 8 years | |
| Kenneth Lock | M | 50 | 6 years | |
| Hunter Gillies | M | 58 | 5 years | |
| Yuan Xu | M | 56 | 1 years | |
| John Sundy | M | 62 | 6 years | |
| Charles Winter | M | - | 4 years | |
| Christophe Quéva | M | 57 | 3 years | |
| Rolf Carlsson | M | - | 2 years | |
| Elvia Cowan | F | 51 | 3 years | |
| Elizabeth Ann Fagan | M | 74 | 2 years | |
| Arvinder Dhalla | M | - | 6 years | |
| William Guyer | M | 56 | 6 years | |
| Marni Kottle | F | - | 8 years | |
| Ron Sarkar | M | - | 5 years | |
| Mani Subramanian | M | - | 9 years | |
| Stephen Cheng | M | - | 7 years | |
| Ashraf Amanullah | M | 56 | 4 years | |
| Smital Shah | F | 48 | 2 years | |
| Qing Qing Yi | M | 52 | - | |
| Philip T. Sager | M | 68 | 1 years | |
| Anthony D. Caracciolo | M | 68 | 13 years | |
| Kenneth F. Boehm | M | - | 11 years | |
| Robert Nelsen | M | 60 | 1 years | |
| Louis Lange | M | 72 | - | |
| Helen Kim | F | 61 | 2 years | |
| Sapna R. Srivastava | M | 53 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 2 years |
| Kevin B. Young | M | 66 | 10 years | |
| Muzammil Mansuri | M | 70 | 6 years | |
| Alan Montgomery | M | 70 | 5 years | |
| Stan Blackburn | M | 68 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | - |
| Roy Baynes | M | 69 | 1 years | |
| Susan T. Hubbard | F | - | 23 years | |
| Langdon L. Miller | M | 70 | 2 years | |
| David Gollaher | M | 74 | 4 years | |
| Scott Ogg | M | 57 | 2 years | |
| Tse Li Yang | F | 51 | 12 years | |
| Christopher Griffith | M | 47 | 5 years | |
| Phillip Gutry | M | 50 | 5 years | |
| Jakob Dupont | M | 58 | 2 years | |
| Maria Fardis | M | 56 | 11 years | |
| Robert Janssen | M | 70 | 2 years | |
| Jung Choi | F | 54 | 8 years | |
| Philippe C. Bishop | M | 59 | 2 years | |
| Jeffrey Hessekiel | M | 55 | 10 years | |
| Craig S. Gibbs | M | 61 | 21 years | |
| Noreen Henig | M | 59 | 6 years | |
| William T. Symonds | M | 56 | 2 years | |
| Michael Sofia | M | 66 | - | |
| Christopher Senner | M | 56 | 5 years | |
| Ramin Farzaneh-Far | M | 47 | 3 years | |
| Pawel Trawkowski | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nicole White
- Personal Network
